

# Christina Pfannenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9134848/publications.pdf>

Version: 2024-02-01

50  
papers

2,367  
citations

257450

24  
h-index

206112

48  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [ <sup>18</sup> F]FMISO PET/CT. <i>Radiotherapy and Oncology</i> , 2022, 171, 30-36.	0.6	22
2	Impact of PET/CT on management of patients with esophageal cancer – results from a PET/CT registry study. <i>European Journal of Radiology</i> , 2021, 136, 109524.	2.6	3
3	Impact of <sup>18</sup> F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. <i>BJR   Open</i> , 2021, 3, 20210008.	0.6	5
4	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i> <sup>18</sup> F-FDG-PET. <i>Theranostics</i> , 2020, 10, 925-937.	10.0	46
5	Impact of PET/CT on clinical management in patients with cancer of unknown primary – a PET/CT registry study. <i>European Radiology</i> , 2020, 30, 1325-1333.	4.5	17
6	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. <i>European Journal of Radiology</i> , 2020, 131, 109242.	2.6	1
7	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 52-59.	2.9	2
8	Is there a link between very early changes of primary and secondary lymphoid organs in <sup>18</sup> F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
9	Determinants of activity of brown adipose tissue in lymphoma patients. <i>Scientific Reports</i> , 2020, 10, 21802.	3.3	5
10	Influence of <sup>18</sup> F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2313-2321.	6.4	5
11	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing <sup>18</sup> F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. <i>Cancer Imaging</i> , 2020, 20, 44.	2.8	13
12	Effects of simulated dose variation on contrast-enhanced CT-based radiomic analysis for Non-Small Cell Lung Cancer. <i>European Journal of Radiology</i> , 2020, 124, 108804.	2.6	11
13	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic <sup>18</sup> F-FMISO PET for Head and Neck Cancer Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1698-1704.	5.0	37
14	Intention-to-Treat Analysis of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1359-1365.	5.0	29
15	Impact of diverse chemotherapeutic agents and external factors on activation of brown adipose tissue in a large patient collective. <i>Scientific Reports</i> , 2019, 9, 1901.	3.3	7
16	EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 278.	2.7	16
17	Value of CT iterative metal artifact reduction in PET/CT – clinical evaluation in 100 patients. <i>British Journal of Radiology</i> , 2019, 92, 20180756.	2.2	12
18	Practice-based evidence for the clinical benefit of PET/CT – results of the first oncologic PET/CT registry in Germany. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 54-64.	6.4	30

#	ARTICLE	IF	CITATIONS
19	Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers?. <i>European Journal of Radiology</i> , 2018, 99, 94-102.	2.6	18
20	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 95-101.	6.4	46
21	Correlation of Brown Adipose Tissue with Other Body Fat Compartments and Patient Characteristics. <i>Academic Radiology</i> , 2018, 25, 102-110.	2.5	57
22	Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. <i>Radiologia Medica</i> , 2018, 123, 860-870.	7.7	26
23	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. <i>Radiotherapy and Oncology</i> , 2017, 124, 526-532.	0.6	107
24	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1312-1318.	6.4	23
25	Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. <i>Acta Oncologica</i> , 2017, 56, 1577-1582.	1.8	20
26	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. <i>Acta Oncologica</i> , 2017, 56, 1571-1576.	1.8	23
27	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. <i>European Radiology</i> , 2017, 27, 2538-2545.	4.5	10
28	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 92-101.	6.4	237
29	SUV-quantification of physiological lung tissue in an integrated PET/MR-system: Impact of lung density and bone tissue. <i>PLoS ONE</i> , 2017, 12, e0177856.	2.5	10
30	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 482-488.	6.4	37
31	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 634-643.	6.4	20
32	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. <i>Acta Oncologica</i> , 2015, 54, 1364-1369.	1.8	22
33	Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? – Variability induced by different SUV measurements and varying reconstruction methods. <i>European Journal of Radiology</i> , 2015, 84, 158-162.	2.6	42
34	Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 677-684.	6.4	31
35	Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. <i>Abdominal Imaging</i> , 2013, 38, 64-71.	2.0	75
36	Correlation of Simultaneously Acquired Diffusion-Weighted Imaging and 2-Deoxy-[18F] fluoro-2-D-glucose Positron Emission Tomography of Pulmonary Lesions in a Dedicated Whole-Body Magnetic Resonance/Positron Emission Tomography System. <i>Investigative Radiology</i> , 2013, 48, 247-255.	6.2	68

#	ARTICLE	IF	CITATIONS
37	Multifunctional Profiling of Non- <sup>18</sup> F-FDG PET/CT and Volume Perfusion CT. <i>Journal of Nuclear Medicine</i> , 2012, 53, 521-529.	5.0	49
38	Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. <i>Abdominal Radiology</i> , 2012, 37, 834-842.	2.1	31
39	PET/CT with 18F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 845-853.	5.0	36
40	Impact of Age on the Relationships of Brown Adipose Tissue With Sex and Adiposity in Humans. <i>Diabetes</i> , 2010, 59, 1789-1793.	0.6	349
41	<sup>18</sup> F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2009, 16, 1295-1303.	1.5	141
42	Positron Emission Tomography/Computed Tomography and Whole-Body Magnetic Resonance Imaging in Staging of Advanced Non-small Cell Lung Cancer: Initial Results. <i>Investigative Radiology</i> , 2008, 43, 290-297.	6.2	47
43	Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. <i>British Journal of Radiology</i> , 2007, 80, 437-445.	2.2	96
44	Prospective comparison of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. <i>European Journal of Cancer</i> , 2007, 43, 557-564.	2.8	188
45	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. <i>European Journal of Cancer</i> , 2006, 42, 342-350.	2.8	100
46	Fast Whole-Body Assessment of Metastatic Disease Using a Novel Magnetic Resonance Imaging System. <i>Investigative Radiology</i> , 2005, 40, 64-71.	6.2	101
47	Dual-phase multidetector thin-section CT in detecting duodenal gastrinoma. <i>Abdominal Imaging</i> , 2005, 30, 543-547.	2.0	17
48	Bildgebende Diagnostik von Metastasen in Hirn, Knochen, Leber und Lunge. <i>Onkologie</i> , 2004, 10, 504-516.	0.7	4
49	The role of [ <sup>18</sup> F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors: prospects for management. <i>World Journal of Urology</i> , 2004, 22, 132-9.	2.2	40
50	MR cholangiography in the diagnosis of sclerosing cholangitis in Langerhans' cell histiocytosis. <i>European Radiology</i> , 2001, 11, 2516-2520.	4.5	14